Protocol Ledger

NCT05527340 · Phase II · ACTIVE NOT RECRUITING

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

Interventional Phase II clinical trial protocol NCT05527340 sponsored by PETHEMA Foundation in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-15 Enrollment: 140 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05527340
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)140 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05527340
Protocol FieldVerified Registry Value
NCT IdentifierNCT05527340
Consolidated Lead SponsorPETHEMA Foundation
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment140 participants (ESTIMATED)
Registered Start Date2022-12-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI